Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSC trial of acetylcysteine after out-of-hospital cardiac arrest
2025-525094-37-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of acetylcysteine in cardiac arrest (SCA) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in oxidized low-density lipoprotein. Planned start Oct 2026; status: authorised.
02
Drugs
acetylcysteine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on 2025-525094-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525094-37-00.